Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibraxine is a prebiotic dietary supplement developed by Alfasigma (formerly Alfa Wassermann). It is a combination product containing partially hydrolyzed guar gum (PHGG) and lactoferrin. PHGG is a water-soluble fiber that serves as a prebiotic substrate, selectively stimulating the growth and activity of beneficial gut bacteria such as *Bifidobacterium* and *Lactobacillus*. This fermentation process produces short-chain fatty acids (SCFAs), which help regulate intestinal motility and improve stool consistency. Lactoferrin, a multifunctional glycoprotein, contributes to the maintenance of gut homeostasis and supports the intestinal immune system. Fibraxine is primarily used to support digestive health and manage symptoms associated with functional gastrointestinal disorders, such as irritable bowel syndrome (IBS) and chronic constipation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fibraxine.